Our top story in June came from a modified Delphi study presented at the Global Spine Congress 2022 (1–4 June; Las Vegas, USA) which provided expert consensus on the application of lateral lumbar interbody fusion. Additional research from the meeting, a feature on the future of awake spine surgery and industry news from the likes of Globus Medical, Stryker, 3Spine, SI-Bone, SeaSpine and Novarad also made it into the most popular stories on Spinal News International.
A modified Delphi method has been used to ascertain expert consensus from the Chinese Study Group for Lateral Lumbar Spine Surgery in an effort to inform clinical decision-making in the application of lateral lumbar interbody fusion (LLIF). The results of the study were presented by Yong Hai (Beijing Chaoyang Hospital, Beijing, China) at the Global Spine Congress 2022 (1–4 June; Las Vegas, USA) where it won the Global Spine Journal Best Paper award.
Two experts outline their views on whether or not awake spine surgery will gain significant traction over the coming years.
Globus Medical has announced the first surgeries performed using its intraoperative three-in-one imaging platform, Excelsius3D.
Stryker has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for its Q Guidance System, which—when used with the company’s Spine Guidance Software—is a planning and intraoperative guidance system designed to enable open or percutaneous computer-assisted surgery.
Revision discectomy is associated with higher rates of subsequent lumbar fusion (SLF) and faster time to SLF that primary discectomy at eight-year follow-up. This is according to research published in The Spine Journal by Sheeraz Qureshi (Hospital for Special Surgery, New York, USA) et al.
Heavier patients frequently receive an inadequate weight-based dose of preoperative cefazolin and as such have an increased risk of infection following spinal fusion surgery. This is according to the findings of a recent study, presented at Global Spine Congress (GSC) 2022 (1–4 June; Las Vegas, USA) by Mark Lambrechts (Rothman Orthopaedic Institute, Philadelphia, USA).
3Spine has announced US Food and Drug Administration (FDA) investigational device exemption (IDE) approval for a US pivotal clinical trial for their MOTUS spinal implant.
SI-Bone has announced that it has received US Food and Drug Administration (FDA) 510(k) premarket clearance for its iFuse Bedrock Granite implant system (Granite)—which is designed to provide sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion.
SeaSpine has announced the full commercial launch of its 3D-printed WaveForm TO (transforaminal lumbar interbody fusion [TLIF] oblique) interbody system which has been designed for both TLIF and posterior lumbar interbody fusion (PLIF) procedures.
VisAR, an augmented reality surgical navigation system from healthcare technology company Novarad, has received US Food and Drug Administration (FDA) 510(k) approval for precision guided intraoperative spine surgery.